COMPASSION‑16 Phase 3 data showed cadonilimab added to chemotherapy, with or without bevacizumab, improved outcomes for first‑line treatment of advanced cervical cancer. Investigators presented results at the ASCO Genitourinary Cancers Symposium, documenting efficacy signals that could expand I/O options in a disease with limited first‑line immunotherapy choices. The lead sentence: the trial demonstrated that combining a PD‑1/CTLA‑4 bispecific antibody with chemotherapy meaningfully increases response compared with historical controls, altering the therapeutic calculus for frontline care. The study delineates cohorts, safety profiles, and progression‑free survival metrics relevant to regulatory strategy and clinical adoption.